444 related articles for article (PubMed ID: 20392299)
1. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.
Vernaleken I; Janouschek H; Raptis M; Hellmann S; Veselinovic T; Bröcheler A; Boy C; Cumming P; Hiemke C; Rösch F; Schäfer WM; Gründer G
Int J Neuropsychopharmacol; 2010 Aug; 13(7):951-60. PubMed ID: 20392299
[TBL] [Abstract][Full Text] [Related]
2. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
Gründer G; Landvogt C; Vernaleken I; Buchholz HG; Ondracek J; Siessmeier T; Härtter S; Schreckenberger M; Stoeter P; Hiemke C; Rösch F; Wong DF; Bartenstein P
Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387
[TBL] [Abstract][Full Text] [Related]
3. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
Vernaleken I; Fellows C; Janouschek H; Bröcheler A; Veselinovic T; Landvogt C; Boy C; Buchholz HG; Spreckelmeyer K; Bartenstein P; Cumming P; Hiemke C; Rösch F; Schäfer W; Wong DF; Gründer G
J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
[TBL] [Abstract][Full Text] [Related]
4. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
[TBL] [Abstract][Full Text] [Related]
5. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.
Kessler RM; Ansari MS; Riccardi P; Li R; Jayathilake K; Dawant B; Meltzer HY
Neuropsychopharmacology; 2006 Sep; 31(9):1991-2001. PubMed ID: 16738543
[TBL] [Abstract][Full Text] [Related]
6. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study.
Stephenson CM; Bigliani V; Jones HM; Mulligan RS; Acton PD; Visvikis D; Ell PJ; Kerwin RW; Pilowsky LS
Br J Psychiatry; 2000 Nov; 177():408-15. PubMed ID: 11059993
[TBL] [Abstract][Full Text] [Related]
7. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
[TBL] [Abstract][Full Text] [Related]
8. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
Nikisch G; Baumann P; Kiessling B; Reinert M; Wiedemann G; Kehr J; Mathé AA; Piel M; Roesch F; Weisser H; Schneider P; Hertel A
J Psychiatr Res; 2010 Sep; 44(12):754-9. PubMed ID: 20176367
[TBL] [Abstract][Full Text] [Related]
9. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.
Kessler RM; Ansari MS; Riccardi P; Li R; Jayathilake K; Dawant B; Meltzer HY
Neuropsychopharmacology; 2005 Dec; 30(12):2283-9. PubMed ID: 16123775
[TBL] [Abstract][Full Text] [Related]
10. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
11. Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine.
Tauscher J; Küfferle B; Asenbaum S; Brücke T; Kasper S
Psychopharmacology (Berl); 1997 Sep; 133(1):102-5. PubMed ID: 9335088
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
Tuppurainen H; Kuikka JT; Viinamäki H; Husso M; Tiihonen J
Psychiatry Clin Neurosci; 2009 Aug; 63(4):529-37. PubMed ID: 19496999
[TBL] [Abstract][Full Text] [Related]
13. Alteration of dopamine D2/D3 receptor binding in patients with juvenile myoclonic epilepsy.
Landvogt C; Buchholz HG; Bernedo V; Schreckenberger M; Werhahn KJ
Epilepsia; 2010 Sep; 51(9):1699-706. PubMed ID: 20384765
[TBL] [Abstract][Full Text] [Related]
14. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
[TBL] [Abstract][Full Text] [Related]
15. Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride.
Riccardi P; Baldwin R; Salomon R; Anderson S; Ansari MS; Li R; Dawant B; Bauernfeind A; Schmidt D; Kessler R
Biol Psychiatry; 2008 Jan; 63(2):241-4. PubMed ID: 17586476
[TBL] [Abstract][Full Text] [Related]
16. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.
Kegeles LS; Slifstein M; Xu X; Urban N; Thompson JL; Moadel T; Harkavy-Friedman JM; Gil R; Laruelle M; Abi-Dargham A
Biol Psychiatry; 2010 Oct; 68(7):634-41. PubMed ID: 20673873
[TBL] [Abstract][Full Text] [Related]
17. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
18. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.
Seeman P; Tallerico T
Am J Psychiatry; 1999 Jun; 156(6):876-84. PubMed ID: 10360126
[TBL] [Abstract][Full Text] [Related]
19. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
[TBL] [Abstract][Full Text] [Related]
20. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
